Lipocine Is One To Watch Based On Possible FDA Approval Of TLANDO And NASH DataSeeking Alpha • 11/11/21
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2021PRNewsWire • 11/10/21
Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-Cirrhotic NASHPRNewsWire • 11/04/21
Lipocine Announces Multiple Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021PRNewsWire • 11/01/21
Lipocine And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO®PRNewsWire • 10/18/21
Lipocine to Present at The Cantor Fitzgerald Virtual Global Healthcare ConferencePRNewsWire • 09/20/21
Lipocine to Present at The H.C. Wainwright 23rd Annual Global Investment ConferencePRNewsWire • 09/01/21
Lipocine's LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT StudyPRNewsWire • 08/25/21
Lipocine Announces Presentations at The International Liver Congress™ 2021 Digital EventPRNewsWire • 06/23/21
Lipocine To Start Testing Neuro-Steroid Candidate In Postpartum Depression PatientsBenzinga • 06/14/21